Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

GREENSBORO, N.C., Oct. 25, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla.

These data include an extension of the Phase III, randomized, placebo-controlled, double-blind trial that assessed the safety and efficacy of XEOMIN in blepharospasm, which was recently published in the July 2011 issue of Movement Disorders, the official journal of the Movement Disorders Society. Findings from the Phase III trial demonstrate that XEOMIN was significantly more efficacious than placebo, as observed in the primary efficacy variable (change in Jankovic Rating Scale severity subscore six weeks following treatment), when administered in a single treatment session to patients with blepharospasm who were previously treated with onabotulinumtoxinA (Botox®).Blepharospasm, also referred to as benign essential blepharospasm, is a rare condition that possibly goes undiagnosed or misdiagnosed. Botulinum toxin is the only FDA-approved medication for the treatment of this condition. The U.S. Food and Drug Administration (FDA) approved XEOMIN in July 2010 for the treatment of blepharospasm in adults who have been previously treated with Botox®.

"XEOMIN studies led to clinically relevant reductions in the severity of symptoms such as excessive blinking and eyelid spasms," said lead author of the Movement Disorders publication Joseph Jankovic, MD, Professor of Neurology and Director of the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas. "The results demonstrate the safety and efficacy of XEOMIN for the treatmen
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... , , INCLINE VILLAGE, Nev., ... today reported financial results for the second quarter ended June 30, 2009. ... second quarter of 2009 were $125.9 million, an 18 percent increase from ... primarily to royalty revenues driven by higher product sales of Avastin(R), and ...
... , , , HAYWARD, ... a global leader in the medical aesthetics market, today announced results for ... $27.4 million, an increase of approximately $9.5 million, or 53%, as compared ... the acquisition of Reliant Technologies, Inc. on December 23, 2008. The company ...
... , , , ... GXDX ), a specialized laboratory services provider, today reported revenues of ... $3.7 million benefit from changes in accounting estimates resulting primarily from ... increased 62.8% over revenues of $27.8 million for the comparable period ...
... 30 Nephros, Inc. (OTC Bulletin Board: NEPH), a medical ... infection control, and water purification, today reported that it has ... and warrants to purchase additional common stock for aggregate proceeds ... is pleased to have completed this financing, which was led ...
... , STEWARTVILLE, Minn., July 30 Rochester Medical ... quarter ended June 30, 2009. , , The Company reported ... quarter of last year. The Company also reported net loss of $77,000 ... $312,000 or $.02 per diluted share for the same period of last year. ...
... , , ... GPRO ) today reported financial results for the second ... and record sexually transmitted disease (STD), clinical diagnostics and total product ... the second quarter of 2009 as a good performance from our ...
Cached Medicine News:Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 2Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 3Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 4Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 5Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 6Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 7Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 8Health News:PDL BioPharma Announces Second Quarter 2009 Financial Results 9Health News:Solta Medical Reports Strong Second Quarter 2009 Results 2Health News:Solta Medical Reports Strong Second Quarter 2009 Results 3Health News:Solta Medical Reports Strong Second Quarter 2009 Results 4Health News:Solta Medical Reports Strong Second Quarter 2009 Results 5Health News:Solta Medical Reports Strong Second Quarter 2009 Results 6Health News:Solta Medical Reports Strong Second Quarter 2009 Results 7Health News:Solta Medical Reports Strong Second Quarter 2009 Results 8Health News:Solta Medical Reports Strong Second Quarter 2009 Results 9Health News:Solta Medical Reports Strong Second Quarter 2009 Results 10Health News:Solta Medical Reports Strong Second Quarter 2009 Results 11Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 2Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 3Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 4Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 5Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 6Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 7Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 8Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 9Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 10Health News:Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009 11Health News:Nephros, Inc. Completes $1.25 Million Private Placement 2Health News:Nephros, Inc. Completes $1.25 Million Private Placement 3Health News:Rochester Medical Reports Third Quarter Results 2Health News:Rochester Medical Reports Third Quarter Results 3Health News:Rochester Medical Reports Third Quarter Results 4Health News:Rochester Medical Reports Third Quarter Results 5Health News:Rochester Medical Reports Third Quarter Results 6
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
... system features an advanced design that accommodates ... system gives surgeons the flexibility to easily ... Flexibility is built-in to every aspect of ... innovative Secure-TwistTM anti-migration system to the screw ...
... The SC-Acufix anterior cervical plate system is ... patented, integrated swivel, which provides for consistent, ... prevents bone screw disengagement or backout. This ... secondary locking screw. Simply implant your screws ...
Medicine Products: